Melanoma and immunotherapy
Invited discussant abstracts 344O and 351O
Date
21 Dec 2015Session
Melanoma and immunotherapyPresenters
Grant McArthurAuthors
G. McArthurAuthor affiliations
- Peter MacCallum Cancer Centre, Melbourne/AU
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
1246 - Cost-effectiveness of nivolumab in combination with ipilimumab in patients with unresectable advanced melanoma in Australia
Presenter: Megan Bohensky
Session: Melanoma and immunotherapy
Resources:
Abstract
1307 - Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non–small cell lung cancer
Presenter: Keiichi Ota
Session: Melanoma and immunotherapy
Resources:
Abstract
640 - A phase I study of pegylated interferon alfa-2b as an adjuvant therapy in Japanese patients with malignant melanoma
Presenter: Shusuke Yoshikawa
Session: Melanoma and immunotherapy
Resources:
Abstract
705 - A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
Presenter: Shanshan Jiang
Session: Melanoma and immunotherapy
Resources:
Abstract
1151 - Evaluation of safety, tolerability, pharmacokinetics (PK) and efficacy of dabrafenib and trametinib combination (Dab + Tra) therapy in Japanese patients (pts) with BRAF V600 mutation-positive advanced cutaneous melanoma: a phase (Ph) I/II study
Presenter: Arata Tsutsumida
Session: Melanoma and immunotherapy
Resources:
Abstract
741 - BRAF mutation status – a good prognostic indicator in the era of targeted therapies?
Presenter: Luke McLean
Session: Melanoma and immunotherapy
Resources:
Abstract
Invited discussant abstracts 345PD and 352PD
Presenter: Ignacio Melero
Session: Melanoma and immunotherapy
Resources:
Slides
Webcast